Page 20«..10..19202122..3040..»

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to two new employees with grant date of December 1, 2020, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved on October 27, 2020 and November 16, 2020, in accordance with Nasdaq Listing Rule 5635(c)(4).

See the original post:
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

To Read More: Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | dataDecember 5th, 2020
Read All

Orphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization

By Dr. Matthew Watson

­­Orphazyme A/SInvestor news                                                                                                       No. 07/2020                                                                                                          Company Registration No. 32266355

Read the rest here:
Orphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization

To Read More: Orphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization
categoriaGlobal News Feed commentoComments Off on Orphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization | dataDecember 2nd, 2020
Read All

Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with…

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors that will enter a pivotal Phase 3 study CRIMSON 1 this month.

See the rest here:
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with...

To Read More: Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with…
categoriaGlobal News Feed commentoComments Off on Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with… | dataDecember 2nd, 2020
Read All

Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide

By Dr. Matthew Watson

BUFFALO, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its subsidiary, Athenex Pharmaceutical Division (APD), has launched Liquid, Ready-To-Dilute Cyclophosphamide. The product is being brought to market through APD’s co-marketing partnership with Ingenus Pharmaceuticals, LLC. APD will leverage existing commercial relationships with hospitals, integrated health systems, which include U.S. cancer centers, major distributors, and GPOs, to optimize distribution and commercial uptake of Liquid, Ready-To-Dilute Cyclophosphamide. In 2019, Athenex’s specialty pharmaceuticals business sold into nearly 2,800 oncology hospitals, critical care sites, and clinics.

Read more from the original source:
Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide

To Read More: Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide
categoriaGlobal News Feed commentoComments Off on Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide | dataDecember 2nd, 2020
Read All

Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs

By Dr. Matthew Watson

Proceeds support expanded clinical program of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity Proceeds support expanded clinical program of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity

Continue reading here:
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs

To Read More: Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
categoriaGlobal News Feed commentoComments Off on Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs | dataDecember 2nd, 2020
Read All

Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split

By Dr. Matthew Watson

DUBLIN, Ireland, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Global Select Market as of the commencement of trading on December 3, 2020.

Go here to see the original:
Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split

To Read More: Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split
categoriaGlobal News Feed commentoComments Off on Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split | dataDecember 2nd, 2020
Read All

Motus GI and Memorial Hermann Hospital Partner to Improve its Colonoscopy Efficiencies

By Dr. Matthew Watson

FORT LAUDERDALE, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today a collaboration with Dr. Nirav Thosani, Director of Advanced Endoscopy, Memorial Hermann Hospital in Houston, Texas, to incorporate the Company’s Pure-Vu® System with the aim of improving efficiencies and clinical outcomes of inpatient colonoscopy procedures at Memorial Hermann Hospital, for patients who present with inadequate bowel preparation. The Memorial Hermann Hospital is a flagship hospital within the Memorial Hermann System, which is one of the largest not-for-profit health systems in Texas, owning and operating 14 hospitals.

See the original post:
Motus GI and Memorial Hermann Hospital Partner to Improve its Colonoscopy Efficiencies

To Read More: Motus GI and Memorial Hermann Hospital Partner to Improve its Colonoscopy Efficiencies
categoriaGlobal News Feed commentoComments Off on Motus GI and Memorial Hermann Hospital Partner to Improve its Colonoscopy Efficiencies | dataDecember 2nd, 2020
Read All

Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

By Dr. Matthew Watson

CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function.

Go here to read the rest:
Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

To Read More: Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer
categoriaGlobal News Feed commentoComments Off on Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer | dataDecember 2nd, 2020
Read All

COVID-19 Vaccine Capable Air Transportation System Patent Awarded to Reflect Scientific for its Liquid Nitrogen Temperature-controlled Cooling and…

By Dr. Matthew Watson

OREM, Utah, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announced a patent has been granted by the United States Patent Office for an ultracold shipping and storage container for transportation by air that uses liquid nitrogen technology for cooling.

Originally posted here:
COVID-19 Vaccine Capable Air Transportation System Patent Awarded to Reflect Scientific for its Liquid Nitrogen Temperature-controlled Cooling and...

To Read More: COVID-19 Vaccine Capable Air Transportation System Patent Awarded to Reflect Scientific for its Liquid Nitrogen Temperature-controlled Cooling and…
categoriaGlobal News Feed commentoComments Off on COVID-19 Vaccine Capable Air Transportation System Patent Awarded to Reflect Scientific for its Liquid Nitrogen Temperature-controlled Cooling and… | dataDecember 2nd, 2020
Read All

SteroTherapeutics, LLC signs CRADA Agreement with NIH to Develop a Novel Treatment for Cushing Syndrome Patients

By Dr. Matthew Watson

SPRING HOUSE, Pa., Dec. 02, 2020 (GLOBE NEWSWIRE) -- SteroTherapeutics, LLC, a biopharmaceutical company developing new treatments for patients with rare diseases announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to complete a Phase 2 clinical trial to determine the safety, efficacy, and dosage regimen for a non-androgenic analogue of dehydroepiandrosterone (DHEA) in the treatment of the manifestations of Cushing syndrome (also referred to as Cushing’s syndrome) including metabolic syndrome and fatty liver disease which is found in up to 25% of adult Cushing syndrome patients.

Original post:
SteroTherapeutics, LLC signs CRADA Agreement with NIH to Develop a Novel Treatment for Cushing Syndrome Patients

To Read More: SteroTherapeutics, LLC signs CRADA Agreement with NIH to Develop a Novel Treatment for Cushing Syndrome Patients
categoriaGlobal News Feed commentoComments Off on SteroTherapeutics, LLC signs CRADA Agreement with NIH to Develop a Novel Treatment for Cushing Syndrome Patients | dataDecember 2nd, 2020
Read All

Enzo Biochem to Report First Quarter 2021 Financial Results on Wednesday, December 9

By Dr. Matthew Watson

Conference Call and Webcast Scheduled for December 9, 2020, 4:30 pm ET

Go here to read the rest:
Enzo Biochem to Report First Quarter 2021 Financial Results on Wednesday, December 9

To Read More: Enzo Biochem to Report First Quarter 2021 Financial Results on Wednesday, December 9
categoriaGlobal News Feed commentoComments Off on Enzo Biochem to Report First Quarter 2021 Financial Results on Wednesday, December 9 | dataDecember 2nd, 2020
Read All

Single-Dose Radiation Therapy At Time Of Lumpectomy Helps Breast Cancer Patients Overcome Treatment Challenges During Pandemic

By Dr. Matthew Watson

Read more here:
Single-Dose Radiation Therapy At Time Of Lumpectomy Helps Breast Cancer Patients Overcome Treatment Challenges During Pandemic

To Read More: Single-Dose Radiation Therapy At Time Of Lumpectomy Helps Breast Cancer Patients Overcome Treatment Challenges During Pandemic
categoriaGlobal News Feed commentoComments Off on Single-Dose Radiation Therapy At Time Of Lumpectomy Helps Breast Cancer Patients Overcome Treatment Challenges During Pandemic | dataDecember 2nd, 2020
Read All

Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer

By Dr. Matthew Watson

Appointment strengthens leadership team ahead of tebipenem HBr’s potential commercialization Appointment strengthens leadership team ahead of tebipenem HBr’s potential commercialization

Read more:
Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer

To Read More: Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer
categoriaGlobal News Feed commentoComments Off on Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer | dataDecember 2nd, 2020
Read All

Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors

By Dr. Matthew Watson

LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors, effective November 30, 2020.

Continue reading here:
Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors

To Read More: Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors
categoriaGlobal News Feed commentoComments Off on Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors | dataDecember 2nd, 2020
Read All

Syneos Health Announces Pricing of Secondary Offering of Common Stock

By Dr. Matthew Watson

MORRISVILLE, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 6,000,000 shares of the Company’s common stock (the “Offering”) at a price to the public of $61.90 per share. Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the selling stockholders in the Offering. The Offering is expected to close on December 3, 2020, subject to customary closing conditions.

Read more here:
Syneos Health Announces Pricing of Secondary Offering of Common Stock

To Read More: Syneos Health Announces Pricing of Secondary Offering of Common Stock
categoriaGlobal News Feed commentoComments Off on Syneos Health Announces Pricing of Secondary Offering of Common Stock | dataDecember 2nd, 2020
Read All

Yield10 Bioscience Researcher Dr. Meghna Malik to Present at the 4th CRISPR AgBio Congress 2020 Virtual Event

By Dr. Matthew Watson

WOBURN, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that Meghna Malik, Ph.D., Senior Director, will present at the 4th CRISPR AgBio Congress which is being held December 1-3, 2020 as a virtual event.

Read the original:
Yield10 Bioscience Researcher Dr. Meghna Malik to Present at the 4th CRISPR AgBio Congress 2020 Virtual Event

To Read More: Yield10 Bioscience Researcher Dr. Meghna Malik to Present at the 4th CRISPR AgBio Congress 2020 Virtual Event
categoriaGlobal News Feed commentoComments Off on Yield10 Bioscience Researcher Dr. Meghna Malik to Present at the 4th CRISPR AgBio Congress 2020 Virtual Event | dataDecember 2nd, 2020
Read All

Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed/refractory multiple myeloma on December 5, 2020 via a live webinar at 11:00 AM Pacific Time/2:00 PM Eastern Time.

See the rest here:
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020

To Read More: Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020
categoriaGlobal News Feed commentoComments Off on Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020 | dataDecember 2nd, 2020
Read All

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

By Dr. Matthew Watson

MELBOURNE, Australia, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (“Agreement”).

Visit link:
Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

To Read More: Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX
categoriaGlobal News Feed commentoComments Off on Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX | dataDecember 2nd, 2020
Read All

RoosterBio Collaborates with Sartorius to Expand Cell and Gene Therapy Manufacturing Platform Technology into South Korea

By Dr. Matthew Watson

The partnership launches RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia The partnership launches RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia

Continued here:
RoosterBio Collaborates with Sartorius to Expand Cell and Gene Therapy Manufacturing Platform Technology into South Korea

To Read More: RoosterBio Collaborates with Sartorius to Expand Cell and Gene Therapy Manufacturing Platform Technology into South Korea
categoriaGlobal News Feed commentoComments Off on RoosterBio Collaborates with Sartorius to Expand Cell and Gene Therapy Manufacturing Platform Technology into South Korea | dataDecember 2nd, 2020
Read All

Axiom will be Presenting and Exhibiting at Clinical Trials in Rare Diseases 2020: A Virtual Event

By Dr. Matthew Watson

TORONTO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, is a presenting sponsor and exhibitor at Clinical Trials in Rare Diseases taking place December 7-8th, 2020.

Continue reading here:
Axiom will be Presenting and Exhibiting at Clinical Trials in Rare Diseases 2020: A Virtual Event

To Read More: Axiom will be Presenting and Exhibiting at Clinical Trials in Rare Diseases 2020: A Virtual Event
categoriaGlobal News Feed commentoComments Off on Axiom will be Presenting and Exhibiting at Clinical Trials in Rare Diseases 2020: A Virtual Event | dataDecember 2nd, 2020
Read All

Page 20«..10..19202122..3040..»